Cowen & Co. Sticks to Its Buy Rating for Seres Therapeutics (MCRB)


In a report issued on May 3, Chris Shibutani from Cowen & Co. maintained a Buy rating on Seres Therapeutics (MCRB). The company’s shares closed yesterday at $5.07, close to its 52-week low of $4.42.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.6% and a 44.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $12, which is a 136.7% upside from current levels. In a report issued on May 2, Chardan Capital also reiterated a Buy rating on the stock with a $15 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.75 and a one-year low of $4.42. Currently, Seres Therapeutics has an average volume of 375.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts